# Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.

> **NCT05777902** · PHASE4 · TERMINATED · sponsor: **I.R.C.C.S. Fondazione Santa Lucia** · enrollment: 30 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ozanimod Oral Capsule

## Key facts

- **NCT ID:** NCT05777902
- **Lead sponsor:** I.R.C.C.S. Fondazione Santa Lucia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-31
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05777902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05777902, "Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05777902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*